Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Ipatasertib · GDC-0068, RG-7440

Small molecule · Inhibitor of Akt (AKT1) · developed by Hoffmann-La Roche

Phase 1/2 Most advanced trial
1 Registered trials

What is Ipatasertib?

Ipatasertib is an orally bioavailable inhibitor of Akt that binds and inhibits the kinase in a non-ATP-competitive manner. It is studied in metastatic breast cancer to inhibit PI3K/Akt signaling, suppress tumor cell proliferation, and induce apoptosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
GDC-0068, RG-7440
Drug type
Small molecule
Targets
Akt (AKT1)
Mechanism
Inhibitor of Akt (AKT1)
Pathways
PI3K/Akt signaling, apoptosis
Therapy area
Oncology
Developer
Hoffmann-La Roche
In trials of
GILD
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
524Y3IB4HQ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03424005 Phase 1/2 Metastatic Breast Cancer Recruiting GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Breast Cancer

Other drugs acting on AKT1

Olverembatinib Phase 3

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.